 |
|
|
| |
GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects
|
| |
| |
Reported by Jules Levin
18th Conference on Retroviruses and Opportunistic Infections March 2, 2011 Paper # 152LB
M Markowitz,1 A Zolopa,2* P Ruane,3 K Squires,4 L Zhong,5 BP Kearney,5 and W Lee5
1Aaron Diamond AIDS Research Center, New York, NY; 2Stanford University Positive Care Clinic, Palo Alto, CA; 3Lighthouse Medical, Los Angeles, CA; 4Thomas Jefferson University, Philadelphia, PA;
5Gilead Sciences, Foster City, CA
GS7430 is the new tenfovir prodrug and the results from a new phase 1b study was just presented at CROI. It was much more potent than tenofovir in patients, is supposedcto have the potential to have lower risk for side effects and toxicities because it is delivered into PBMCs rather than plasma where TDF is delivered. It has HBV activity and should be more potent also in HBV. The viral load reduction after 14 days was I as much as -1.71 log with 150 mg and -1.57 with the 50 mg dose, 2 doses were explored: 50 and 150 mg of GS7430. Patients could switch from TDF to GS7430 eventually. No renal data was presented in this very early study but it looks promising and future renal evaluations studies are planned.
|
| |
|
|
|
|
|
